Hyderabad, Jan. 24 -- The United States Food and Drug Administration (FDA) has approved Spravato, a nasal spray by Johnson & Johnson as a stand-alone treatment for adults with Major Depressive Disorder (MDD).
The spray is a first of its kind, as it provides a stand-alone solution for treatment-resistant depression which is when at least two standard treatments fail to ease depression symptoms.
The spray first entered the US market in 2019 and was previously cleared to be used together with an oral antidepressant for treatment-resistant depression as well as for treating patients with MDD experiencing thoughts of suicide and harm.
Usage and more
Spravato can be used with or without an oral antidepressant especially if pills cause unwan...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.